Teacher Retirement System of Texas Has $334,000 Stock Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Teacher Retirement System of Texas boosted its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 24.6% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 28,652 shares of the company’s stock after purchasing an additional 5,665 shares during the period. Teacher Retirement System of Texas’ holdings in Intellia Therapeutics were worth $334,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. Regeneron Pharmaceuticals Inc. bought a new position in shares of Intellia Therapeutics in the 4th quarter worth $43,177,000. State Street Corp lifted its position in Intellia Therapeutics by 17.9% in the 3rd quarter. State Street Corp now owns 5,143,534 shares of the company’s stock valued at $105,700,000 after acquiring an additional 780,754 shares in the last quarter. Raymond James Financial Inc. bought a new stake in shares of Intellia Therapeutics in the fourth quarter valued at about $4,793,000. ARK Investment Management LLC boosted its position in Intellia Therapeutics by 2.3% during the 4th quarter. ARK Investment Management LLC now owns 12,536,386 shares of the company’s stock worth $146,174,000 after acquiring an additional 280,946 shares during the last quarter. Finally, Two Sigma Advisers LP boosted its holdings in Intellia Therapeutics by 33.5% during the third quarter. Two Sigma Advisers LP now owns 1,027,617 shares of the company’s stock worth $21,118,000 after purchasing an additional 257,700 shares during the last quarter. 88.77% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on NTLA shares. BMO Capital Markets decreased their price objective on shares of Intellia Therapeutics from $70.00 to $50.00 and set an “outperform” rating for the company in a research report on Friday, January 10th. Morgan Stanley downgraded Intellia Therapeutics from an “overweight” rating to an “equal weight” rating and lowered their price target for the stock from $56.00 to $11.00 in a research report on Monday, January 27th. StockNews.com raised Intellia Therapeutics to a “sell” rating in a research report on Monday, March 3rd. Chardan Capital decreased their target price on Intellia Therapeutics from $91.00 to $68.00 and set a “buy” rating on the stock in a report on Friday, February 28th. Finally, HC Wainwright started coverage on Intellia Therapeutics in a report on Wednesday, March 5th. They set a “buy” rating and a $30.00 price target for the company. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $37.56.

Insider Activity

In other Intellia Therapeutics news, CEO John M. Leonard sold 26,807 shares of the business’s stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $12.18, for a total value of $326,509.26. Following the completion of the sale, the chief executive officer now directly owns 941,115 shares of the company’s stock, valued at $11,462,780.70. The trade was a 2.77 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In the last quarter, insiders have sold 29,000 shares of company stock worth $352,551. 3.20% of the stock is currently owned by corporate insiders.

Intellia Therapeutics Stock Performance

Intellia Therapeutics stock opened at $6.66 on Wednesday. Intellia Therapeutics, Inc. has a fifty-two week low of $6.59 and a fifty-two week high of $28.18. The firm’s fifty day moving average price is $9.86 and its 200-day moving average price is $13.52. The stock has a market cap of $689.42 million, a P/E ratio of -1.22 and a beta of 1.97.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.